Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 351

Sort by

Sort Order Select

Journal Articles

Integrated clinico-biological profiling identifies a high-risk epigenetic signature in Mantle Cell Lymphoma: A lysa study

Blood (2025) 146 (Supplement 1): 661.

https://doi.org/10.1182/blood-2025-661

Published: 2025

Journal Articles

Comparison of axicabtagene ciloleucel to standard regimens as second line treatment for large B cell lymphoma in real life: A lysa study from descar-T and realysa registries

Gabriel Brisou, Aurelien Belot, Emmanuel Bachy, Herve Ghesquieres, François-Xavier Gros, Krimo Bouabdallah, Guillaume Cartron, Roberta Di Blasi, Roch Houot, Cedric Rossi, Amandine Durand, Fabien Le Bras, Corinne Haioun, Thomas Gastinne, Remy Dulery, Pierre Bories, Fabrice Jardin, Blandine Guffroy, Luc-Matthieu Fornecker, Cristina Castilla-Llorente, Gandhi Damaj, Franck Morschhauser, Michael Loschi, Stephanie Guidez, Choquet Sylvain, Aline Schmidt, Laurianne Drieu La Rochelle, Marie-Thérèse Rubio, Sylvain Carras, Jacques-Olivier Bay, Adrien Chauchet, Magalie Joris, Ludovic Fouillet, Laure Lebras, Julie Abraham, Fontanet Bijou, Olivier Hermine, Antoine Bonnet, Justine Decroocq, Sandy Amorim, Nadine Morineau, Pauline Lionne, Sophie Dennetiere, Laura Herbreteau, Bernard Drenou, Launay Vincent, Gaelle Olivier, Gaëlle Labouré, Olivier Fitoussi, Christophe Fruchart, Cecile Leyronnas, Fanny Cherblanc, Elodie Gat, Benoit Tessoulin

Blood (2025) 146 (Supplement 1): 2764.

https://doi.org/10.1182/blood-2025-2764

Published: 2025

Journal Articles

Impact of the number of bridging therapy lines on outcomes after axi-cel in LBCL: A lysa study from the descar-T registry

Blood (2025) 146 (Supplement 1): 2745.

https://doi.org/10.1182/blood-2025-2745

Published: 2025

Journal Articles

Prognostic value of combining beta-2-microglobulin and total metabolic tumor volume in patients with follicular lymphoma: A post-hoc analysis of the relevance trial

Blood (2025) 146 (Supplement 1): 5361.

https://doi.org/10.1182/blood-2025-5361

Published: 2025

Journal Articles

Assessment of the prognostic value of FDG PET-derived markers and responses in POLARIX

Anne-Ségolène Cottereau, Alex Herrera, Hervé Tilly, Gilles Salles, Loïc Chartier, Matthew Sugidono, Skander Jemaa, Richard Carano, Connie Lee Batlevi, Greg Hapgood, Georg Lenz, Franck Morschhauser

Blood (2025) 146 (Supplement 1): 5329.

https://doi.org/10.1182/blood-2025-5329

Published: 2025

Journal Articles

Long-term immune reconstitution and final 1-year follow-up after fixed-duration venetoclax-obinutuzumab (VenO) in first-line (1L) chronic lymphocytic leukemia (CLL): Results from the Phase III CRISTALLO trial

Hyun Yong Jin, Jeff Sharman, Luca Laurenti, Emmanuelle Ferrant, Luis Felipe Casado Montero, Stephen Mulligan, Rosemary Harrup, Stephen Opat, Adalberto Ibatici, Roberto Marasca, Paolo Sportoletti, Archie Egginton, Maria Thadani-Mulero, Oscar Cazarez, Yanwen Jiang, Michelle Boyer, Franck Morschhauser

Blood (2025) 146 (Supplement 1): 682.

https://doi.org/10.1182/blood-2025-682

Published: 2025

Journal Articles

Anti-CD19 CAR-T cells for Mantle Cell Lymphoma with central nervous system involvement: A study of the french descart registry.

Stephanie Guidez, Marie-Thérèse Rubio, Roberta Di Blasi, Gabriel Brisou, Morgane Cheminant, Emmanuel Bachy, Franck Morschhauser, Cristina Castilla-Llorente, Blandine Guffroy, Roch Houot, Steven Le Gouill, Olivier Hermine, Fabien Le Bras, Laure Ricard, Damien Roos Weil

Blood (2025) 146 (Supplement 1): 3598.

https://doi.org/10.1182/blood-2025-3598

Published: 2025

Journal Articles

Early time-to-relapse as a predictor of survival in mature T-cell/NK-cell lymphomas: Results from the PETAL consortium

Mark Sorial, Kenechukwu Aniagboso, Emily Buttermore, Matthew Lei, Ellen Kendall, Kristiana Nasto, Min Jung Koh, Jessy Xinyi Han, Leora Boussi, Luis Malpica, Brady Beltran, Laura Korin, German Stemmelin, Carlos Chiattone, Denisse Castro, Fabiola Valvert, Jule Vasquez, Henry Quintero, Macarena Roa, Alfredo Quiroz, Marialejandra Torres Viera, Luis Mario Villela Martinez, Ana Oliver, Cesar Augusto Samanez Figari, Edith Julia, Vincent Camus, Catherine Thieblemont, Philippe Gaulard, Laurence de Leval, Franck Morschhauser, Emmanuel Bachy, Omar Elghawy, Stefan Barta, Jack Malespini, Kusha Chopra, Caroline MacVicar, Sean McCabe, Luke Peng, Shambhavi Singh, Makoto Iwasaki, Ijeoma Eche-Ugwu, Judith Gabler, Maria J Fernandez, Alexander Disciullo, Josie Ford, Alexandra Lenart, Emmanuel Nwodo, Jeffrey Barnes, Min Ji Koh, Eliana Miranda, Robert Stuver, Mwanasha Merrill, Eric Jacobsen, Martina Manni, Monica Civallero, Tetiana Skrypets, Athina Lymboussaki, Massimo Federico, Yu Ri Kim, Jin Seok Kim, Jae Yong Cho, Thomas Eipe, Tanuja Shet, Epari Sridhar, Alok Shetty, Saswata Saha, Manju Sengar, Hasmukh Jain, Carrie Van Der Weyden, H. Miles Prince, Ramzi Hamouche, Tinatin Muradashvili, Francine Foss, Marianna Gentilini, Beatrice Casadei, Pier Luigi Zinzani, Takeshi Okatani, Noriaki Yoshida, Sang Eun Yoon, Won-Seog Kim, Girisha Panchoo, Zainab Mohamed, Estelle Verburgh, Jackielyn Cuenca Alturas, Mubarak Al Mansour, Maria Elena Cabrera, Govind Bhagat, Helen Ma, Ahmed Sawas, Dhruv Mistry, Khyati Kariya, Forum Bhanushali, Maya Krishnan, Erica Lee, Owen O'Conner, Enrica Marchi, Devavrat Shah, Changyu Shen, Salvia Jain

Blood (2025) 146 (Supplement 1): 889.

https://doi.org/10.1182/blood-2025-889

Published: 2025

Journal Articles

Center effect on large B-cell lymphoma outcome in frontline prospective Phase II and III trials : A lysa study

Tristan Robert-Van Houtteghem, Marguerite Fournier, Fabrice Jardin, Pierre Feugier, François Lemonnier, Loic Ysebaert, Franck Morschhauser, Laure Lebras, Cedric Rossi, Vincent Ribrag, Catherine Thieblemont, Aurelien Belot, Emmanuel Bachy

Blood (2025) 146 (Supplement 1): 4495.

https://doi.org/10.1182/blood-2025-4495

Published: 2025

Journal Articles

BMS-986458, a first-in-class, bifunctional cereblon-dependent ligand-directed degrader of B-cell lymphoma 6 (BCL6) in patients with Relapsed/Refractory (R/R) non-Hodgkin lymphoma (NHL): Updated results from the Phase 1 dose escalation study

Blood (2025) 146 (Supplement 1): 480.

https://doi.org/10.1182/blood-2025-480

Published: 2025

Journal Articles

Golcadomide (GOLCA), a potential, first-in-class, oral CELMoD™ agent, ± rituximab (R) in patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL): Phase 1/2 study extended follow-up Results

Blood (2025) 146 (Supplement 1): 479.

https://doi.org/10.1182/blood-2025-479

Published: 2025

Journal Articles

Valemetostat monotherapy in patients with relapsed or refractory B-cell lymphoma: Final results of the Phase 2 valym study from the lysa

Blood (2025) 146 (Supplement 1): 1797.

https://doi.org/10.1182/blood-2025-1797

Published: 2025

Journal Articles

Epcoritamab + R-mini-CHOP results in 2-year remissions and high MRD negativity rates in elderly patients with newly diagnosed DLBCL: Results from the EPCORE NHL-2 trial

Blood (2025) 146 (Supplement 1): 64.

https://doi.org/10.1182/blood-2025-64

Published: 2025

Journal Articles

Fixed-duration epcoritamab monotherapy induces high response and MRD-negativity rates in elderly patients with newly diagnosed large B-cell lymphoma (LBCL) and comorbidities: Results from EPCORE DLBCL-3

Blood (2025) 146 (Supplement 1): 63.

https://doi.org/10.1182/blood-2025-63

Published: 2025

Journal Articles

Persistent B-cell aplasia predicts late severe infections after anti-CD19 CAR T-cell treatment in B-cell lymphoma : A methodological approach to long-term safety reporting

Blood (2025) 146 (Supplement 1): 6297.

https://doi.org/10.1182/blood-2025-6297

Published: 2025

Journal Articles

Glofitamab is superior to non a-CD3xC20 treatments for patients with diffuse large B-cell lymphoma who are refractory or relapse immediately after anti-CD19 CAR T-cell therapy: Final results of the bicar study (LYSA) and indirect comparison with a synthetic control arm from the descart registry.

Blood (2025) 146 (Supplement 1): 1958.

https://doi.org/10.1182/blood-2025-1958

Published: 2025

Journal Articles

Pre-manufacturing CD8+ central-memory type 2 T cells predict axicabtagene ciloleucel failure in large B-cell lymphoma

Blood (2025) 146 (Supplement 1): 1945.

https://doi.org/10.1182/blood-2025-1945

Published: 2025

Journal Articles

Health-related quality of life (HRQoL) in patients with relapsed/refractory follicular lymphoma treated with epcoritamab in combination with rituximab plus lenalidomide (E+R2): Primary results of the EPCORE FL-1 trial

Kim Linton, Franck Morschhauser, Marcel Nijland, Huiqiang Huang, John Seymour, Catherine Thieblemont, Abualbishr Alshreef, Jennifer Lord-Bessen, Rajesh Kamalakar, Zhijie Ding, Gauri Sunkersett, Jian Mei, Lorenzo Falchi

Blood (2025) 146 (Supplement 1): 5370.

https://doi.org/10.1182/blood-2025-5370

Published: 2025

Journal Articles

Preliminary efficacy and safety of the Bruton tyrosine kinase degrader BGB-16673 in patients with relapsed/refractory Richter transformation: Results from the ongoing phase 1 CaDAnCe-101 study

Meghan Thompson, Annamaria Frustaci, John Seymour, John Allan, Paolo Ghia, Olivier Dumas, Franck Morschhauser, Martin Dreyling, Stephan Stilgenbauer, Inhye Ahn, Romain Guieze, Yanan Zhang, Linlin Xu, Kunthel By, Shannon Fabre, Daniel Persky, Amit Agarwal, Carlo Visco

Blood (2025) 146 (Supplement 1): 3895.

https://doi.org/10.1182/blood-2025-3895

Published: 2025

Journal Articles

Outcomes and treatment patterns of patients with primary mediastinal b-cell lymphoma after CAR-t cell therapy failure : A descar-t analysis

Blood (2025) 146 (Supplement 1): 3733.

https://doi.org/10.1182/blood-2025-3733

Published: 2025

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Integrated clinico-biological profiling identifies a high-risk epigenetic signature in Mantle Cell Lymphoma: A lysa study

Comparison of axicabtagene ciloleucel to standard regimens as second line treatment for large B cell lymphoma in real life: A lysa study from descar-T and realysa registries

Impact of the number of bridging therapy lines on outcomes after axi-cel in LBCL: A lysa study from the descar-T registry

Prognostic value of combining beta-2-microglobulin and total metabolic tumor volume in patients with follicular lymphoma: A post-hoc analysis of the relevance trial

Assessment of the prognostic value of FDG PET-derived markers and responses in POLARIX

Long-term immune reconstitution and final 1-year follow-up after fixed-duration venetoclax-obinutuzumab (VenO) in first-line (1L) chronic lymphocytic leukemia (CLL): Results from the Phase III CRISTALLO trial

Anti-CD19 CAR-T cells for Mantle Cell Lymphoma with central nervous system involvement: A study of the french descart registry.

Early time-to-relapse as a predictor of survival in mature T-cell/NK-cell lymphomas: Results from the PETAL consortium

Center effect on large B-cell lymphoma outcome in frontline prospective Phase II and III trials : A lysa study

BMS-986458, a first-in-class, bifunctional cereblon-dependent ligand-directed degrader of B-cell lymphoma 6 (BCL6) in patients with Relapsed/Refractory (R/R) non-Hodgkin lymphoma (NHL): Updated results from the Phase 1 dose escalation study

Golcadomide (GOLCA), a potential, first-in-class, oral CELMoD™ agent, ± rituximab (R) in patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL): Phase 1/2 study extended follow-up Results

Valemetostat monotherapy in patients with relapsed or refractory B-cell lymphoma: Final results of the Phase 2 valym study from the lysa

Epcoritamab + R-mini-CHOP results in 2-year remissions and high MRD negativity rates in elderly patients with newly diagnosed DLBCL: Results from the EPCORE NHL-2 trial

Fixed-duration epcoritamab monotherapy induces high response and MRD-negativity rates in elderly patients with newly diagnosed large B-cell lymphoma (LBCL) and comorbidities: Results from EPCORE DLBCL-3

Persistent B-cell aplasia predicts late severe infections after anti-CD19 CAR T-cell treatment in B-cell lymphoma : A methodological approach to long-term safety reporting

Glofitamab is superior to non a-CD3xC20 treatments for patients with diffuse large B-cell lymphoma who are refractory or relapse immediately after anti-CD19 CAR T-cell therapy: Final results of the bicar study (LYSA) and indirect comparison with a synthetic control arm from the descart registry.

Pre-manufacturing CD8+ central-memory type 2 T cells predict axicabtagene ciloleucel failure in large B-cell lymphoma

Health-related quality of life (HRQoL) in patients with relapsed/refractory follicular lymphoma treated with epcoritamab in combination with rituximab plus lenalidomide (E+R2): Primary results of the EPCORE FL-1 trial

Preliminary efficacy and safety of the Bruton tyrosine kinase degrader BGB-16673 in patients with relapsed/refractory Richter transformation: Results from the ongoing phase 1 CaDAnCe-101 study

Outcomes and treatment patterns of patients with primary mediastinal b-cell lymphoma after CAR-t cell therapy failure : A descar-t analysis

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only